MAGEA3 and neoplasm: While MAGEA3 and MUC1 have been established as immunogenic tumor antigens capable of generating anti-tumor T cell responses, it is possible that encoding only one tumor antigen in a lung cancer vaccine formulation is not sufficient to broadly prolong survival [121,122,141,147,148].